Fbdaf53c E60c 4f8c 9af5 Ce08e8ca65f0 4 5005 C


The major statistical survey on the health status and living conditions of French citizens in connection with the current coronavirus pandemic (Covid-19)

In this video, Anne-Lise Beaumont, Rémonie Seng and Josiane Warszawski present the first results of the study and its perspectives during the CESP scientific symposium, 13/11/2020


– Young people aged 15-24 years, immigrants and descendants of immigrants from outside Europe were more affected by the virus during the second wave
– Seroprevalence rises sharply among young adults and in Auvergne-Rhône-Alpes
– Seroprevalence decreases with age, from 10% in those under 25 years old to 4% in those over 64 years old
– Densely populated areas and healthcare professions remain the most exposed
– Nearly three out of four infected people have experienced symptoms

Description of the Study:

  • Title: EpiCOV.
  • Principal investigators: Nathalie Bajos and Josiane Warszawski.
  • Centers of Implementation: National Institute of Health and Medical Research (Inserm) and the Directorate of Research, Studies, Evaluation and Statistics (Drees) of the Ministry of Solidarity and Health.
  • Study Population: 135,000 French citizens which were randomly selected by INSEE to represent the entire French population.
  • Study Type: Epidemiological.
  • Design: A first questionnaire was sent to the 135,000 participants in May of 2020. In October-November of the same year, a second questionnaire was sent, which would help to describe the evolution of the epidemic since May.

Objectives of the Study:

Principal Objective: To provide, on the one hand, an accurate mapping of the immune status of the population, health, living conditions and social inequalities regarding these 3 parameters, and, on the other hand, a monitoring of epidemic dynamics in the short, medium and long term.

More about this Study:

Scientific Context: According to the French Ministry of Solidarity and Health, “Quantifying the proportion of people who have developed antibodies in response to the SARS-CoV2 virus and documenting the effects of this epidemic on the living conditions of our fellow citizens appear to be major issues to support the development of the most appropriate decontainment and prevention strategies, allow the early detection of any epidemic resumption and, in the longer term, monitor the effectiveness of the measures taken.”

Preliminary results: “From the 135,000 replies to the May questionnaire and the 12,000 serological analyses carried out, important results were obtained on the situation in France in the spring. In metropolitan France, 4.5% of people aged 15 or over had been in contact with the virus in May 2020. This share is higher among 30-49 year olds, in the most densely populated municipalities and for people living in overcrowded housing. The poorest as well as the richest have also been in contact with the virus more often for people in the midst of income distribution.” (EpiCOV website)

Logo Inserm 1600px
Unnamed 2
1200px Sante Publique France Logo
32230767 30083742

Other Studies about Serology:

Effectiveness of vaccine combination

Científicos franceses demuestran que la vacunación primaria con dos vacunas diferentes sería más eficaz que la vacunación con dos vacunas idénticas.


COVID-19 immunity in healthcare professionals

Determining whether there is protection against reinfection is important for controlling healthcare workers implications during the pandemic due to their continous professional contact with COVID-19 patients

COnV-ert study, convalescent plasma to stop COVID-19

Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the severity of symptoms.

Mass SARS-CoV-2 Serological Screening in Andorra

This study aims to estimate the prevalence of antibodies against SARS-CoV-2 and help improve the prediction of infectious diseases and increase biosecurity in the Principality of Andorra.


SAPRIS-SERO is a study to estimate the seroprevalence of SARS-CoV-2 infection in the epidemiological cohorts Constances, E3-E4N, NutriNet-Santé and Elfe-Epipage2 in France.


Identifying true markers of protective immunity will allow for the identification of individuals, in particular healthcare personnel working with COVID-19 patients and in other critical areas protected from re-infection.


The COVICAT study aims to evaluate the evolution of the incidence of SARS-CoV-2 coronavirus infection in the Catalan population over a 12-month period.

Convalescent plasma therapy and COVID-19

Convalescent plasma with anti-SARS-CoV-2 antibodies appears to be a very promising approach in the context of protracted COVID-19 symptoms in patients unable to mount a specific humoral response to SARS-CoV-2.


COVonco Study

Join the COVonco study and help understand the impact of COVID-19 in oncology.

REACT-2.5: Seroprevalence of SARS-CoV-2 antibodies

This cross-sectional study estimates SARS-CoV-2 IgG antibody seroprevalence in the community in England using self-administered LFIAs.